Pregabalin Capsule
Product Images NDC 71610-948

Product Visual Gallery

This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-948). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0948 30)

Pregabalin 200 mg oral capsules packaging label for a bottle of 30 capsules. The label includes storage instructions to keep between 20-25 degrees Celsius and protect from light and humidity. It notes the product is RX only and manufactured by SciGen Pharmaceuticals Inc., with labeler Aphena Pharma Solutions - Tennessee, LLC. The label also includes a warning that the medication may be habit forming.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

Chemical structure diagram of pregabalin, showing its molecular framework with amino and carboxyl functional groups.*

FDA Label Image

Figure 1 (Pregabalin 02)

A line graph showing the percent of patients improved versus percent improvement in pain from baseline for Pregabalin doses (200 mg, 100 mg, and 25 mg, each taken three times a day) and placebo. The graph compares efficacy across different dosage groups with percent improvement on the x-axis and percent of patients improved on the y-axis.*

FDA Label Image

Figure 2 (Pregabalin 03)

A line graph showing the percent of patients improved plotted against percent improvement in pain from baseline, comparing Pregabalin 100 mg three times a day with placebo. The graph includes two lines representing each treatment's effectiveness in patient pain improvement over the range of 0 to 100 percent.*

FDA Label Image

Figure 3 (Pregabalin 04)

A line graph illustrating the percent of patients improved versus percent improvement in pain from baseline for Pregabalin at doses of 75 mg, 150 mg, and 300 mg twice daily, compared to placebo. The graph shows trends of patient improvement across different improvement percentages.*

FDA Label Image

Figure 4 (Pregabalin 05)

A line chart depicting the percent of patients improved relative to percent improvement in pain from baseline. The graph compares three groups: Pregabalin 200 mg three times a day, Pregabalin 100 mg three times a day, and placebo. The y-axis represents percent of patients improved, and the x-axis shows percent improvement in pain from baseline, ranging from 0 to 100 percent.*

FDA Label Image

Figure 5 (Pregabalin 06)

Line graph showing percent of patients improved on the vertical axis versus percent improvement in pain on the horizontal axis. It compares three groups: Pregabalin 100 mg three times a day, Pregabalin 50 mg three times a day, and a placebo. Two vertical lines mark points on the horizontal axis near 30 and 50 percent improvement in pain.*

FDA Label Image

Figure 6 (Pregabalin 07)

A bar chart comparing responder rates (%) across different doses of Pregabalin and placebo in two clinical studies labeled E1 and E3. The x-axis shows treatment groups including placebo, 50 mg/day, 150 mg/day, 300 mg/day, and 600 mg/day doses with dosing frequencies BID or TID. The y-axis represents the responder rate percentage, with values increasing from left to right in both studies.*

FDA Label Image

Figure 7 (Pregabalin 08)

A line graph depicting seizure reduction as median percentage change from baseline against pregabalin dose (mg/day). Four data series represent different studies and dosing schedules, with markers indicating significant p-values (≤0.0001 and 0.0007). The graph compares placebo to varying doses up to 600 mg/day for human prescription drug Pregabalin capsules.*

FDA Label Image

Figure 9 (Pregabalin 09)

A line graph showing percent of patients improved versus percent improvement in pain from baseline. It compares four groups: Pregabalin daily doses of 600 mg, 450 mg, 300 mg, and placebo, with each dose represented by different line styles.*

FDA Label Image

Figure 10 (Pregabalin 10)

A line graph comparing the estimated percentage of subjects without LTR over 180 days between Pregabalin and placebo groups. The vertical axis shows percentage from 0% to 100%, and the horizontal axis shows days from 0 to 180. The Pregabalin group maintains a higher percentage without LTR compared to the placebo group throughout the period.*

FDA Label Image

Figure 11 (Pregabalin 11)

A line graph comparing the percent of subjects improved from baseline to week 12 using the Brief Pain Inventory Change from Baseline (BPCF). It plots percent improvement on the x-axis (from >0 to 100) against the percent of subjects improved on the y-axis (0 to 100), showing two lines representing Pregabalin and Placebo groups.*

FDA Label Image

Figure 12 (Pregabalin 12)

A line graph depicting the percent of subjects improved from baseline to Week 16 BOCF, comparing Pregabalin and Placebo groups. The x-axis represents the percent improvement, and the y-axis shows the percent of subjects improved, with higher values on the left. Two lines illustrate the comparisons between the Pregabalin and Placebo groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.